Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Animals
Biomarkers, Tumor
/ analysis
Cell Line, Tumor
Cytokines
/ analysis
Exosomes
/ metabolism
Extracellular Vesicles
/ metabolism
Exudates and Transudates
/ metabolism
Humans
Lymph
/ metabolism
Lymph Node Excision
Lymphatic Metastasis
Lymphatic Vessels
/ metabolism
Melanoma
/ blood
Mice
Mice, Inbred C57BL
MicroRNAs
/ analysis
Proteomics
/ methods
S100 Proteins
/ analysis
Skin Neoplasms
/ blood
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
06 05 2019
06 05 2019
Historique:
received:
22
08
2018
revised:
21
12
2018
accepted:
20
03
2019
pubmed:
13
4
2019
medline:
6
5
2020
entrez:
13
4
2019
Statut:
ppublish
Résumé
Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137
Identifiants
pubmed: 30975896
pii: jem.20181618
doi: 10.1084/jem.20181618
pmc: PMC6504224
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
MicroRNAs
0
S100 Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1091-1107Subventions
Organisme : NIA NIH HHS
ID : R01 AG045223
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137198
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146180
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219304
Pays : United States
Informations de copyright
© 2019 Broggi et al.
Références
Nat Med. 2001 Feb;7(2):199-205
pubmed: 11175851
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Anal Chem. 2003 Sep 1;75(17):4646-58
pubmed: 14632076
Proteomics. 2004 Mar;4(3):753-65
pubmed: 14997497
Clin Exp Metastasis. 1992 May;10(3):145-55
pubmed: 1582084
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
Nat Cell Biol. 2008 Nov;10(11):1349-55
pubmed: 18820689
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Cancer Lett. 2010 Feb 28;288(2):162-9
pubmed: 19646811
PLoS One. 2010 Mar 26;5(3):e9863
pubmed: 20360855
Ann Surg Oncol. 2010 Dec;17(12):3314-23
pubmed: 20607422
Cancer Res. 2011 Jun 1;71(11):3792-801
pubmed: 21478294
Nat Med. 2011 Sep 18;17(10):1290-7
pubmed: 21926977
Nat Med. 2011 Nov 07;17(11):1371-80
pubmed: 22064427
Nat Rev Cancer. 2012 Feb 24;12(3):210-9
pubmed: 22362216
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
J Proteomics. 2013 Jan 14;78:172-87
pubmed: 23202415
PLoS One. 2013;8(2):e57135
pubmed: 23451163
J Mol Med (Berl). 2013 Apr;91(4):431-7
pubmed: 23519402
PLoS One. 2013 Jul 19;8(7):e69354
pubmed: 23894455
Mol Cells. 2013 Nov;36(5):432-8
pubmed: 24158612
Clin Cancer Res. 2014 Jan 1;20(1):3-5
pubmed: 24166912
Front Immunol. 2013 Dec 16;4:424
pubmed: 24379811
J Immunol. 2014 Jun 1;192(11):5002-11
pubmed: 24795456
Nat Commun. 2014 Jun 06;5:3989
pubmed: 24905362
J Vis Exp. 2014 Aug 19;(90):e51803
pubmed: 25178108
Shock. 2014 Dec;42(6):485-498
pubmed: 25243428
Nat Rev Cancer. 2015 Feb;15(2):96-109
pubmed: 25614008
Semin Cancer Biol. 2015 Dec;35 Suppl:S244-S275
pubmed: 25865774
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
Oncotarget. 2015 Oct 20;6(32):32723-36
pubmed: 26416248
Nat Rev Drug Discov. 2015 Nov;14(11):781-803
pubmed: 26471369
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Metastasis Rev. 2015 Dec;34(4):775-96
pubmed: 26573921
Nat Rev Cancer. 2015 Dec;15(12):712-29
pubmed: 26597527
Clin Chim Acta. 2016 Feb 15;454:28-32
pubmed: 26724367
J Biol Chem. 2016 Mar 11;291(11):5576-95
pubmed: 26740625
Mol Oncol. 2016 Mar;10(3):450-63
pubmed: 26778792
Science. 2016 Apr 8;352(6282):242-6
pubmed: 26989197
Sci Rep. 2016 Apr 18;6:24436
pubmed: 27087234
Cancer Discov. 2016 Jul;6(7):703-13
pubmed: 27107038
Science. 2016 May 6;352(6286):658-60
pubmed: 27151852
J Clin Invest. 2016 Sep 1;126(9):3389-402
pubmed: 27525437
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Cancers (Basel). 2016 Dec 10;8(12):
pubmed: 27973407
Circ Res. 2017 Apr 28;120(9):1440-1452
pubmed: 28130294
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5930-E5939
pubmed: 28684402
Trends Cancer. 2016 Jun;2(6):305-312
pubmed: 28741528
Sci Transl Med. 2017 Sep 13;9(407):null
pubmed: 28904226
Oncoimmunology. 2018 May 31;7(8):e1462878
pubmed: 30221058
J Exp Med. 2019 May 6;216(5):1061-1070
pubmed: 30975894